ROLE OF ACYL-COA SYNTHETASE 4 IN EPITHELIAL OVARIAN CANCER

PRADA, JESICA G.; HERNÁNDEZ, ANDREA; GARRIDO, MARITZA P.; ORLANDO, ULISES D.; BIGI, MARÍA M.; ROMERO OSSES, CARMEN ; PODESTA, ERNESTO J.; CASTILLO, ANA F.; MALOBERTI, PAULA M.

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Acyl-CoA synthetase 4 (ACSL4) is involved in arachidonic acid metabolism and steroidogenesis. In pathological scenarios, increased ACSL4 level is associated with promotion of highly aggressive phenotype in breast and prostate cancer. We developed and characterized the effect of PRGL493, a specific ACSL4 inhibitor, in triple negative breast cancer and castration-resistant prostate cancer cell lines, demonstrating that decreased aggressive phenotype based on inhibition of steroidogenesis, chemotherapeutic resistance and tumor growth. Ovarian cancer is the third most common gynecologic malignancy but first in mortality rate and there is evidence that sex-steroid hormones have a role in ovarian carcinogenesis. Therefore, the aim was to analyze the role of ACSL4 in epithelial ovarian cancer (EOC). Bioinformatic analysis based on the cross-over between genetic signatures described in ovarian tumors from patients with EOC and genes regulated by ACSL4 related to processes of proliferation, invasion, migration and transduction signals was performed. The study showed a positive correlation for 32 of 48 genes (p